T2 Biosystems, Inc
TTOO
TTOO was delisted on the 11th of February, 2025.
70 hedge funds and large institutions have $9.92M invested in T2 Biosystems, Inc in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 12 closing their positions.
58% more call options, than puts
Call options by funds: $280K | Put options by funds: $177K
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
4% less funds holding
Funds holding: 73 → 70 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
53% less capital invested
Capital invested by funds: $21.1M → $9.92M (-$11.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
Gagnon Securities
New York
|
+$170K |
| 2 |
VF
Virtu Financial
New York
|
+$136K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$108K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$104K |
| 5 |
Jane Street
New York
|
+$62.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.74M |
| 2 |
Millennium Management
New York
|
-$497K |
| 3 |
N
Natixis
Paris,
France
|
-$491K |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$313K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$152K |
TTOO Hedge Fund Activity: Q4 2021 in Review
70 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in T2 Biosystems, Inc (TTOO) for Q4 2021, worth a combined $9.92M — down 53% from $21.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TTOO and 9 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 15 added.
The largest buyer was Gagnon Securities, adding an estimated $170K. The largest seller was Goldman Sachs, cutting an estimated $1.74M.
- 70 institutional investors held T2 Biosystems, Inc (TTOO) as of Q4 2021, down from 73 in Q3 2021.
- Funds reported $9.92M of T2 Biosystems, Inc stock for Q4 2021, down 53% quarter-over-quarter.
- 9 funds opened new T2 Biosystems, Inc positions in Q4 2021 and 12 closed out, a net change of -3 holders.
- The largest T2 Biosystems, Inc buyer in Q4 2021 was Gagnon Securities, an estimated $170K added.
- The largest T2 Biosystems, Inc seller in Q4 2021 was Goldman Sachs, an estimated $1.74M sold.
Based on aggregated 13F filings for Q4 2021.